| JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms AV Jones, A Chase, RT Silver, D Oscier, K Zoi, YL Wang, H Cario, ... Nature genetics 41 (4), 446-449, 2009 | 474 | 2009 |
| Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient … S Branford, L Fletcher, NCP Cross, MC Müller, A Hochhaus, DW Kim, ... Blood, The Journal of the American Society of Hematology 112 (8), 3330-3338, 2008 | 467 | 2008 |
| Ibrutinib resistance in chronic lymphocytic leukemia RR Furman, S Cheng, P Lu, M Setty, AR Perez, A Guo, J Racchumi, G Xu, ... New England Journal of Medicine 370 (24), 2352-2354, 2014 | 353 | 2014 |
| BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity S Cheng, J Ma, A Guo, P Lu, JP Leonard, M Coleman, M Liu, JJ Buggy, ... Leukemia 28 (3), 649-657, 2014 | 217 | 2014 |
| Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA HE White, P Matejtschuk, P Rigsby, J Gabert, F Lin, Y Lynn Wang, ... Blood, The Journal of the American Society of Hematology 116 (22), e111-e117, 2010 | 185 | 2010 |
| Functional Characterization of BTKC481S mutation that confers ibrutinib resistance: Exploration of alternative kinase inhibitors S Cheng, A Guo, P Lu, J Ma, M Coleman, YL Wang. Leukemia 29, 895-900, 2015 | 177 | 2015 |
| Improving job satisfaction of Chinese doctors: the positive effects of perceived organizational support and psychological capital J Fu, W Sun, Y Wang, X Yang, L Wang Public health 127 (10), 946-951, 2013 | 169 | 2013 |
| Thiazolidinedione activation of peroxisome proliferator-activated receptor γ can enhance mitochondrial potential and promote cell survival YL Wang, KA Frauwirth, SM Rangwala, MA Lazar, CB Thompson Journal of Biological Chemistry 277 (35), 31781-31788, 2002 | 147 | 2002 |
| Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL S Kadri, J Lee, C Fitzpatrick, N Galanina, M Sukhanova, G Venkataraman, ... Blood advances 1 (12), 715-727, 2017 | 125 | 2017 |
| SYK inhibition and response prediction in diffuse large B-cell lymphoma S Cheng, G Coffey, XH Zhang, R Shaknovich, Z Song, P Lu, A Pandey, ... Blood, The Journal of the American Society of Hematology 118 (24), 6342-6352, 2011 | 120 | 2011 |
| The proapoptotic factors Bax and Bak regulate T cell proliferation through control of endoplasmic reticulum Ca2+ homeostasis RG Jones, T Bui, C White, M Madesh, CM Krawczyk, T Lindsten, ... Immunity 27 (2), 268-280, 2007 | 120 | 2007 |
| Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and non-Hodgkin lymphoma SQ Zhang, SM Smith, SY Zhang, Y Lynn Wang Br J Haematol 170, 445-456, 2015 | 105 | 2015 |
| Characterization of ibrutinib‐sensitive and‐resistant mantle lymphoma cells J Ma, P Lu, A Guo, S Cheng, H Zong, P Martin, M Coleman, YL Wang British journal of haematology 166 (6), 849-861, 2014 | 100 | 2014 |
| Segregation of lead in Cu–Zn alloy under electric current pulses XL Wang, JD Guo, YM Wang, XY Wu, BQ Wang Applied physics letters 89 (6), 2006 | 99 | 2006 |
| Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative … Q Chen, P Lu, AV Jones, NCP Cross, RT Silver, YL Wang The Journal of Molecular Diagnostics 9 (2), 272-276, 2007 | 96 | 2007 |
| Molecular actions of sirolimus: sirolimus and mTor RA Kirken, YL Wang Transplantation proceedings 35 (3), S227-S230, 2003 | 94 | 2003 |
| The BUAA-VisNir face database instructions D Huang, J Sun, Y Wang School Comput. Sci. Eng., Beihang Univ., Beijing, China, Tech. Rep. IRIP-TR …, 2012 | 90 | 2012 |
| Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL S Sharma, N Galanina, A Guo, J Lee, S Kadri, C Van Slambrouck, B Long, ... Oncotarget 7 (42), 68833, 2016 | 83 | 2016 |
| Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era C Nabhan, G Raca, YL Wang JAMA Oncol 1 (7), 965-974, 2015 | 83 | 2015 |
| Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer C Wang, J Zhang, Y Wang, T Ouyang, J Li, T Wang, Z Fan, T Fan, B Lin, ... Annals of Oncology 26 (3), 523-528, 2015 | 78 | 2015 |
Shuhua Cheng, PhDIcahn School of Medicine at Mount SinaiVerified email at mountsinai.org
